title: Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).
abstract: Behçet's disease (BD) is a chronic relapsing multisystem disease characterized by oral ulceration, genital ulceration and ocular lesions. Gastrointestinal involvement is rare, often difficult to treat and associated with a high mortality rate. We treated a 47-year-old Korean man with BD who had a recurrent intestinal ulcer with tumor necrosis factor alpha antibody (infliximab); he initially underwent right hemicolectomy due to uncontrolled intestinal bleeding. For patients with intestinal BD who fail to respond to conventional treatment, infliximab may be a safe and effective new therapeutic option.
authors.affiliation: Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
authors.forename: Jung Hoon
authors.initials: JH
authors.lastname: Lee
authors.forename: Tae Nyeun
authors.initials: TN
authors.lastname: Kim
authors.forename: Sun Taek
authors.initials: ST
authors.lastname: Choi
authors.forename: Byung Ik
authors.initials: BI
authors.lastname: Jang
authors.forename: Kyeong-Cheol
authors.initials: KC
authors.lastname: Shin
authors.forename: Sam Beom
authors.initials: SB
authors.lastname: Lee
authors.forename: Young Ran
authors.initials: YR
authors.lastname: Shim
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D003082:Colectomy; D018450:Disease Progression; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab